The cross-national epidemiology of DSM-IV intermittent explosive disorder
- PMID: 27572872
- PMCID: PMC5206971
- DOI: 10.1017/S0033291716001859
The cross-national epidemiology of DSM-IV intermittent explosive disorder
Abstract
Background: This is the first cross-national study of intermittent explosive disorder (IED).
Method: A total of 17 face-to-face cross-sectional household surveys of adults were conducted in 16 countries (n = 88 063) as part of the World Mental Health Surveys initiative. The World Health Organization Composite International Diagnostic Interview (CIDI 3.0) assessed DSM-IV IED, using a conservative definition.
Results: Lifetime prevalence of IED ranged across countries from 0.1 to 2.7% with a weighted average of 0.8%; 0.4 and 0.3% met criteria for 12-month and 30-day prevalence, respectively. Sociodemographic correlates of lifetime risk of IED were being male, young, unemployed, divorced or separated, and having less education. The median age of onset of IED was 17 years with an interquartile range across countries of 13-23 years. The vast majority (81.7%) of those with lifetime IED met criteria for at least one other lifetime disorder; co-morbidity was highest with alcohol abuse and depression. Of those with 12-month IED, 39% reported severe impairment in at least one domain, most commonly social or relationship functioning. Prior traumatic experiences involving physical (non-combat) or sexual violence were associated with increased risk of IED onset.
Conclusions: Conservatively defined, IED is a low prevalence disorder but this belies the true societal costs of IED in terms of the effects of explosive anger attacks on families and relationships. IED is more common among males, the young, the socially disadvantaged and among those with prior exposure to violence, especially in childhood.
Keywords: Cross-national studies; DSM-IV; World Mental Health Surveys; epidemiology; intermittent explosive disorder.
Conflict of interest statement
Declarations of Interest Dr Stein has received research grants and/or consultancy honoraria and/or served on speaker bureaus for Biocodex, Eli-Lilly, GlaxoSmithKline, Lundbeck, Pfizer, Servier, Solvay, and Wyeth. Dr Stein is supported by the Medical Research Council of South Africa (MRC). Dr Kessler has been a consultant for Analysis Group, GlaxoSmithKline Inc., Kaiser Permanente, Merck & Co, Inc., Ortho-McNeil Janssen Scientific Affairs, Pfizer Inc., Sanofi-Aventis Groupe, Shire US Inc., SRA International, Inc., Takeda Global Research & Development, Transcept Pharmaceuticals Inc., Wellness and Prevention, Inc., and Wyeth-Ayerst; has served on advisory boards for Plus One Health Management, Mensante Corporation, Lake Nona Institute, U.S. Preventive Medicine and has had research support for his epidemiological studies from Analysis Group Inc., Bristol-Myers Squibb, Eli Lilly & Company, EPI-Q, Ortho-McNeil Janssen Scientific Affairs., Pfizer Inc., Sanofi-Aventis Groupe, and Shire US, Inc. He owns stock in Datastat, Inc. All other authors have no conflicts of interest to declare.
References
-
- American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders. 5th. APA; Washington, DC: 2013.
-
- Coccaro EF. Intermittent explosive disorder as a disorder of impulsive aggression for DSM-5. American Journal of Psychiatry. 2012;169:577–588. - PubMed
-
- Coccaro EF, Kavoussi RJ, Berman ME, Lish JD. Intermittent explosive disorder-revised: development, reliability, and validity of research criteria. Comprehensive Psychiatry. 1998;39:368–376. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous